The next evolution in cell therapy design.
Modulus is engineering next-generation immune cell therapies, starting with Natural Killer cells rationally designed for the treatment of solid tumors. Convergent DesignTM combines genetic engineering, machine learning, and high-throughput in vivo screening to systematically converge on optimized cell designs. Modulus is committed to the discovery of cell therapies to treat a broad set of patient populations not currently served by existing treatments and plans on using its platform to both develop an internal pipeline of therapeutics as well as enable partners.
We envision a future where the design of cell therapies is guided by machine learning to treat more diseases and patients than ever before.
The Solution?
We are inventing new ways to design immune cell therapies, leveraging gene editing and machine learning to converge on optimally performing cells.